Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688090 · ClinicalTrials.gov registry record · Phase 1
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00688090 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 19 participants.
The verdict
NCT00688090, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.
Interventions
- BIOLOGICAL Biological: MKC1106-MT
- BIOLOGICAL Biological: MKCC1106-MT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688090
The ClinicalTrials.gov registry entry for NCT00688090 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biological: MKC1106-MT is the first listed.
NCT00688090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688090 about?
NCT00688090 is a clinical study titled "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.". A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.
What is the current status of trial NCT00688090?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00688090?
The interventions under investigation include: Biological: MKC1106-MT (BIOLOGICAL), Biological: MKCC1106-MT (BIOLOGICAL).
Who is sponsoring clinical trial NCT00688090?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.